Larimar Therapeutics 미래 성장

Future 기준 확인 0/6

Larimar Therapeutics (는) 각각 연간 6.7% 및 83.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -47.5% 로 예상됩니다.

주요 정보

6.7%

수익 성장률

7.7%

EPS 성장률

Biotechs 수익 성장	42.4%
매출 성장률	83.4%
향후 자기자본 수익률	-47.5%
애널리스트 커버리지	Good
마지막 업데이트	21 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:ZA71 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	12	-145	-170	-119	9
12/31/2025	N/A	-102	-117	-95	10
12/31/2024	N/A	-73	-112	-91	9
9/30/2024	N/A	-65	-59	-58	N/A
6/30/2024	N/A	-58	-43	-43	N/A
3/31/2024	N/A	-45	-36	-36	N/A
12/31/2023	N/A	-37	-34	-33	N/A
9/30/2023	N/A	-33	-31	-31	N/A
6/30/2023	N/A	-33	-27	-27	N/A
3/31/2023	N/A	-33	-28	-28	N/A
12/31/2022	N/A	-35	-28	-28	N/A
9/30/2022	N/A	-35	-29	-29	N/A
6/30/2022	N/A	-44	-36	-35	N/A
3/31/2022	N/A	-47	-39	-38	N/A
12/31/2021	N/A	-51	-42	-42	N/A
9/30/2021	N/A	-56	-44	-44	N/A
6/30/2021	N/A	-49	-43	-43	N/A
3/31/2021	N/A	-48	-44	-44	N/A
12/31/2020	N/A	-42	-42	-42	N/A
9/30/2020	N/A	-34	-40	-40	N/A
6/30/2020	N/A	-33	-35	-35	N/A
3/31/2020	N/A	-25	-26	-26	N/A
12/31/2019	N/A	-23	-23	-23	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ZA71 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ZA71 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ZA71 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ZA71 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: ZA71 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ZA71 (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Larimar Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

New major risk - Revenue and earnings growth

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought €100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Independent Director recently bought €419k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

New 90-day low: €15.00

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

New 90-day high: €18.90

New 90-day high: €18.50

New 90-day high: €15.42

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high - €13.82

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견